07:40 AM EDT, 03/12/2025 (MT Newswires) -- Analysts at RBC Capital Markets and Raymond James raised their price targets on Knight Therapeutics Inc. ( KHTRF ) to $8 from $7, and $8 from $7.50, respectively.

RBC analyst Douglas Miehm maintained an Outperform rating on shares of the Montreal-based specialty pharmaceutical company after it announced the acquisition of Paladin Pharma for $120 Million in cash.

"The acquired portfolio generated revenues of $70 Million in 2024, and management anticipates flat revenues for the portfolio with a small decline in the mature products to be offset by growth in the promoted products," Miehm said in a note to clients.

"We view the acquisition as a synergistic fit and believe it should benefit Knight as it expands its presence in Canada," the analyst said.

Raymond James analyst Michael Freeman maintained an Outperform rating on Knight.

"Paladin generated TTM Rev. of $70 Million, which we expect will be flat during the next couple of years and begin growing as Paladin's in-launch and pipeline products begin contributing more materially," Freeman said in a note to clients.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)